The Bio Report

Engineering T-Cell Engagers for Solid Cancers

T-cell engagers have delivered important advances in blood cancers, but extending their success to solid tumors has proved considerably more difficult. Physical barriers,

Resetting Severe Allergies at Their Cellular Source

For people with severe allergies and mast cell diseases, the risk of a dangerous reaction can shape everyday decisions about food, activities, and family routines. Curren

Innovating ADCs with Dual Targeting and Smarter Delivery

Antibody-drug conjugates have established themselves as an important cancer-treatment modality, but their effectiveness and tolerability in solid tumors can be constraine

Targeting the Brain’s Immune System in Alzheimer’s Disease

Alzheimer’s disease remains one of medicine’s most intractable challenges. While existing therapies may address individual features of the disease, such as amyloid or tau

How Gilead Is Building Durable Oncology and Immunology Franchises

Gilead today stands at an inflection point. Its HIV and broader virology business still account for roughly two-thirds of total revenue, even as oncology has grown into a

Protecting the Brain After Stroke

Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with the physical removal of a clot, the current gold-standard care, s

Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond

Type 1 diabetes is still a disease we manage day‑to‑day rather than prevent, and today’s approaches do little to stop the immune system from attacking beta cells in the f

Unlocking Major Targets with Mini Proteins

Most small molecule drugs and biologics miss a large group of important receptors in the body. These receptors, known as GPCRs, play big roles in major diseases, but they

Addressing a Data Problem to Enable AI-Drug Discovery

AI’s promise in drug discovery is being held back by a simple but stubborn problem: the field doesn’t have enough of the right kind of lab-generated data to train good mo

Turning Multi Specific Antibody Design into an Engineering Discipline with AI

Multi-specific antibodies promise to unlock complex biology that conventional monoclonals can’t touch, but their added mechanisms of action also introduce safety and deve

Addressing the Treatment Gap in Ischemic Stroke

Acute ischemic stroke is both ubiquitous and undertreated. Only a small fraction of patients currently receive clot-busting drugs or mechanical thrombectomy because of th

A Pipeline in a Product that Reimagines Control of Inflammation

Plasma gelsolin is an abundant, endogenous regulator of inflammation that is consumed during severe inflammatory insults. When levels fall too low, patients are at higher

Building a Genetics Engine to Crack the Target Bottleneck

A chronic shortage of high‑quality targets remains one of the biggest constraints in drug discovery, even as therapeutic tools become more powerful and diverse. Regeneron

Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug

Epigenetics, the layer of chemical switches that controls how genes are turned on and off, can act like cancer’s operating system when a single epigenetic enzyme becomes

Rewriting the Rules of Antibody Drug Design

Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways require more nuanced control. Metaph

Mapping Cellular Stress Biology to Tackle Undruggable Targets

Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to capture thousands of intracell

Turning Abandoned Drugs into Breakthroughs

Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, even when there is already comp

Targeting Cancer Survival Genes in Solid Tumors

Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs out, leading to relapse and p

Addressing Treatment Gaps in Gout

Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering for millions of people who are

An Off-the-Shelf Cell Therapy to Calm Cytokine Storms

Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast has spent more than 15 years ind